Post-procedural Administration of Nafamostat Mesilate Showed a Similar Preventive effect Against Post- Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Pre-procedural Administration for Patients with Pancreatobiliary Diseases Who underwent ERCP. -A Prospective Double-blind Randomized Controlled Trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.